Eisai Co., Ltd. (4523.T)

6,634.00 +42.00 (+0.64%) 市場開市。 截至 11:00AM JST。

Eisai Co., Ltd.

4-6-10, Koishikawa
Bunkyo-ku
Tokyo 112-8088
Japan
81 3 3817 3700
https://www.eisai.co.jp

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 11,067

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Haruo Naito	CEO, Representative Corporate Officer & Director	無	無	1947
Mr. Gary Hendler	Senior VP & President of EMEA Region	無	無	1966
Dr. Lynn D. Kramer FAAN, M.D.	Vice President & Chief Clinical Officer - Alzheimer's Disease and Brain Health	無	無	1950
Ms. Yanhui Feng	Senior Vice President	無	無	1972
Dr. Nadeem Sarwar Ph.D.	President	無	無	無
Mitsuru Shomon	VP & CFO	無	無	無
Mr. Yasushi Okada	Representative Corporate Officer, COO, Industry Affairs, China Business & Data Integrity	無	無	1958
Makoto Hoketsu	VP & Chief Information Officer	無	無	無
Mr. Masatomi Akana	Chief Gov. Rel. and IR Officer, SVP of Global Value, Acc., Japan Subs, General, Env. & Safety Aff.	無	無	1967
Mr. Kenta Takahashi	Executive VP of IP, Internal Audit & Control, General Counsel and Chief Compliance Officer	無	無	1959

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 JPY。

描述

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

公司管治

截至 2024年6月29日 止，Eisai Co., Ltd. 的 ISS 管治質素評分為 1。 Pillar 分數正在審核中：1；董事會：1；股東權利：6；現金賠償：1。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。